Review Article
Efficacy and Safety of Mesenchymal Stem Cells in Treatment of Complex Perianal Fistulas: A Meta-Analysis
Table 1
Summary of the eligible randomized controlled trials.
(a) |
| Study | Type of perianal fistula | | Cell type and source | Outcome | Results (healed) |
| Garcia-Olmo et al. [14] (2009) Spain | (1) Crohn (2) Cryptoglandular | 49 | Autologous ASCs | Reepithelialization | 17/24 vs. 4/25 CD: 5/7 MSCs+fibrin glue vs. 1/7 fibrin glue at 8 w; cryptoglandular: 12/17 MSCs+fibrin glue vs. 3/18 fibrin glue at 8 w; | Guadalajara et al. [16] (2012) Spain | (1) Crohn (2) Non-CD | 30 | Autologous ASCs | Reepithelialization+MRI | 10/18 vs. 3/12 CD: 2/4 MSCs+fibrin glue vs. 1/2 fibrin glue at 40 m; | Herreros et al. [17] (2012) Spain | Cryptoglandular | 183 | Autologous ASCs | Reepithelialization+MRI | 51/124 vs. 22/59 25/64 MSCs+26/60 MSCs+fibrin glue vs. 22/59 fibrin glue at 24 w | Molendijk et al. [22] (2015) Netherlands | Crohn | 21 | Allogeneic BMSCs | Reepithelialization+MRI | 7/15 MSCs vs. 2/6 saline solution at 12 w | Panés J [23] (2016) Israel | Crohn | 212 | Allogeneic ASCs | Reepithelialization+MRI | 53/103 MSCs vs. 36/101 saline solution at 24 w | Panés J [26] (2018) Israel | Crohn | 212 | Allogeneic ASCs | Reepithelialization+MRI | 58/103 MSCs vs. 39/101 saline solution in 52 w | Garcia-Arranz M [27] (2019) Spain | Cryptoglandular | 35 | Autologous ASCs | Reepithelialization | 10/20 MSCs+fibrin glue vs. 5/19 fibrin glue at 2 years |
|
|
|
(b) |
| Intervention (mean) | Recurrence | Refractory | AEs | Use of concurrent (anti-TNF) |
| Fixed cell dose | 7 months without recurrence | Yes | | Yes | First: MSCs | Second: MSCs | Fixed cell dose | Two completely healed patients were followed up for 4 years without recurrence | Yes | | Yes | First: MSCs | Second: MSCs | Fixed cell dose | Unknown | Yes | | No | First: MSCs | Second: MSCs | Fixed cell dose | 24 w without recurrence | Yes | | Yes | A: MSCs | B: MSCs | C: MSCs | Fixed cell dose | Being follow-up | Yes | 68/103 in MSCs vs. 66/102 in placebo at 24 w | Yes | MSCs | | | Fixed cell dose | Being follow-up | Yes | 79/103 in MSCs vs. 74/102 in placebo at 52 w | Yes | MSCs | Fixed cell dose | Recurrence of the fistula was observed at 2-year follow-up in eight previously cured patients | Unknown | 7/23 MSCs+fibrin glue vs. 9/21 fibrin glue | No | First: MSCs | Second: MSCs |
|
|